NASDAQ:PDLI - PDL Biopharma Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$2.81 +0.04 (+1.44 %)
(As of 05/25/2018 04:00 PM ET)
Previous Close$2.81
Today's Range$2.77 - $2.84
52-Week Range$2.15 - $3.55
Volume603,240 shs
Average Volume1.54 million shs
Market Capitalization$417.27 million
P/E Ratio4.46
Dividend YieldN/A
Beta0.36

About PDL Biopharma (NASDAQ:PDLI)

PDL Biopharma logoPDL BioPharma, Inc. acquires and manages companies, products, royalty agreements, and debt facilities in the biotechnology, pharmaceutical, and medical device industries in the United States, Europe, and internationally. The company operates in three segments: Income Generating Assets, Pharmaceutical, and Medical Devices. The Income Generating Assets segment consists of notes and other long-term receivables; royalty rights and hybrid notes/royalty receivables; equity investments in healthcare companies; and royalties from issued patents covering the humanization of antibodies, including Avastin, Herceptin, Xolair, Lucentis, Perjeta, Kadcyla, and Tysabri. The Pharmaceutical segment manufactures, markets, and sells prescription medicine products for the treatment of hypertension to wholesalers under the Tekturna and Tekturna HCT names in the United States, as well as under the Rasilez and Rasilez HCT names internationally. The Medical Devices segment manufactures and sells LENSAR laser systems for anterior capsulotomy, lens fragmentation, corneal and arcuate incisions to ophthalmic ambulatory surgical centers, specialty ophthalmic hospitals, and multi-specialty hospitals through a direct sales force. The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006. PDL BioPharma, Inc. was founded in 1986 and is headquartered in Incline Village, Nevada.

Receive PDLI News and Ratings via Email

Sign-up to receive the latest news and ratings for PDLI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:PDLI
CUSIP69329Y10
Phone775-832-8500

Debt

Debt-to-Equity Ratio0.14
Current Ratio10.03
Quick Ratio9.75

Price-To-Earnings

Trailing P/E Ratio4.46
Forward P/E Ratio23.42
P/E GrowthN/A

Sales & Book Value

Annual Sales$320.06 million
Price / Sales1.32
Cash Flow$0.8921 per share
Price / Cash3.15
Book Value$5.60 per share
Price / Book0.50

Profitability

EPS (Most Recent Fiscal Year)$0.63
Net Income$110.74 million
Net Margins33.57%
Return on Equity11.76%
Return on Assets8.04%

Miscellaneous

Employees87
Outstanding Shares150,640,000

PDL Biopharma (NASDAQ:PDLI) Frequently Asked Questions

What is PDL Biopharma's stock symbol?

PDL Biopharma trades on the NASDAQ under the ticker symbol "PDLI."

How will PDL Biopharma's stock buyback program work?

PDL Biopharma announced that its board has approved a stock buyback plan on Monday, September 25th 2017, which permits the company to buyback $25,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization permits the company to buy shares of its stock through open market purchases. Stock buyback plans are typically an indication that the company's board believes its shares are undervalued.

How were PDL Biopharma's earnings last quarter?

PDL Biopharma (NASDAQ:PDLI) posted its earnings results on Thursday, March, 8th. The biotechnology company reported $0.17 earnings per share (EPS) for the quarter. The biotechnology company had revenue of $68.04 million for the quarter. PDL Biopharma had a return on equity of 11.76% and a net margin of 33.57%. View PDL Biopharma's Earnings History.

When is PDL Biopharma's next earnings date?

PDL Biopharma is scheduled to release their next quarterly earnings announcement on Wednesday, August, 1st 2018. View Earnings Estimates for PDL Biopharma.

What price target have analysts set for PDLI?

2 analysts have issued 1-year price targets for PDL Biopharma's shares. Their predictions range from $3.00 to $4.00. On average, they anticipate PDL Biopharma's share price to reach $3.50 in the next twelve months. View Analyst Ratings for PDL Biopharma.

Who are some of PDL Biopharma's key competitors?

Who are PDL Biopharma's key executives?

PDL Biopharma's management team includes the folowing people:
  • Mr. John Peter McLaughlin J.D., CEO & Director (Age 66)
  • Mr. Peter S. Garcia, VP & CFO (Age 56)
  • Mr. Steffen Pietzke, VP of Fin. & Chief Accounting Officer (Age 46)
  • Mr. Christopher L. Stone J.D., VP, Gen. Counsel & Sec. (Age 54)
  • Mr. Dominique P. Monnet, Pres (Age 57)

Has PDL Biopharma been receiving favorable news coverage?

Media headlines about PDLI stock have been trending somewhat positive recently, Accern Sentiment reports. The research firm rates the sentiment of press coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. PDL Biopharma earned a coverage optimism score of 0.01 on Accern's scale. They also gave headlines about the biotechnology company an impact score of 45.80 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near future.

Who are PDL Biopharma's major shareholders?

PDL Biopharma's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (9.62%), Dimensional Fund Advisors LP (7.60%), Northern Trust Corp (3.28%), Schwab Charles Investment Management Inc. (2.26%), Royal Bank of Canada (1.84%) and Kestrel Investment Management Corp (1.08%). View Institutional Ownership Trends for PDL Biopharma.

Which institutional investors are selling PDL Biopharma stock?

PDLI stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Seizert Capital Partners LLC, JPMorgan Chase & Co., California Public Employees Retirement System, Prudential Financial Inc., Federated Investors Inc. PA, Citigroup Inc. and BlackRock Inc.. View Insider Buying and Selling for PDL Biopharma.

Which institutional investors are buying PDL Biopharma stock?

PDLI stock was bought by a variety of institutional investors in the last quarter, including Northern Trust Corp, Dimensional Fund Advisors LP, Matarin Capital Management LLC, Schwab Charles Investment Management Inc., SG Americas Securities LLC, Mackay Shields LLC, Element Capital Management LLC and UBS Group AG. View Insider Buying and Selling for PDL Biopharma.

How do I buy shares of PDL Biopharma?

Shares of PDLI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is PDL Biopharma's stock price today?

One share of PDLI stock can currently be purchased for approximately $2.81.

How big of a company is PDL Biopharma?

PDL Biopharma has a market capitalization of $417.27 million and generates $320.06 million in revenue each year. The biotechnology company earns $110.74 million in net income (profit) each year or $0.63 on an earnings per share basis. PDL Biopharma employs 87 workers across the globe.

How can I contact PDL Biopharma?

PDL Biopharma's mailing address is 932 SOUTHWOOD BLVD, INCLINE VILLAGE NV, 89451. The biotechnology company can be reached via phone at 775-832-8500 or via email at [email protected]


MarketBeat Community Rating for PDL Biopharma (PDLI)

Community Ranking:  1.5 out of 5 (star half star)
Outperform Votes:  104 (Vote Outperform)
Underperform Votes:  243 (Vote Underperform)
Total Votes:  347
MarketBeat's community ratings are surveys of what our community members think about PDL Biopharma and other stocks. Vote "Outperform" if you believe PDLI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PDLI will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

PDL Biopharma (NASDAQ:PDLI) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
2 Wall Street analysts have issued ratings and price targets for PDL Biopharma in the last 12 months. Their average twelve-month price target is $3.50, suggesting that the stock has a possible upside of 24.56%. The high price target for PDLI is $4.00 and the low price target for PDLI is $3.00. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.502.502.502.50
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $3.50$3.50$3.50$3.50
Price Target Upside: 24.56% upside18.24% upside18.24% upside18.24% upside

PDL Biopharma (NASDAQ:PDLI) Consensus Price Target History

Price Target History for PDL Biopharma (NASDAQ:PDLI)

PDL Biopharma (NASDAQ:PDLI) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/27/2017CowenReiterated RatingHold$3.00N/AView Rating Details
8/10/2017Piper Jaffray CompaniesReiterated RatingBuy$4.00MediumView Rating Details
(Data available from 5/26/2016 forward)

Earnings

PDL Biopharma (NASDAQ:PDLI) Earnings History and Estimates Chart

Earnings by Quarter for PDL Biopharma (NASDAQ:PDLI)

PDL Biopharma (NASDAQ:PDLI) Earnings Estimates

Current Year EPS Consensus Estimate: $0.12 EPS
Next Year EPS Consensus Estimate: $0.2 EPS

PDL Biopharma (NASDAQ PDLI) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/1/2018$0.06N/AView Earnings Details
3/8/2018Q4 2017$0.17$68.04 millionViewN/AView Earnings Details
11/2/2017Q3 2017$0.13$0.14$61.86 million$62.75 millionViewN/AView Earnings Details
8/3/2017Q2 2017$0.09$0.26$56.30 million$143.80 millionViewListenView Earnings Details
5/3/2017Q1 2017$0.05$0.08$45.44 millionViewListenView Earnings Details
11/3/2016Q316$0.08$0.08$50.69 million$53.60 millionViewN/AView Earnings Details
8/4/2016Q216$0.08$0.09$33.46 million$21.00 millionViewN/AView Earnings Details
5/4/2016Q116$0.50$0.52$142.05 million$103.10 millionViewN/AView Earnings Details
2/22/2016Q415$0.54$0.61$149.20 million$178.10 millionViewListenView Earnings Details
11/4/2015Q315$0.61$0.42$164.80 million$124.60 millionViewN/AView Earnings Details
8/5/2015Q215$0.52$0.47$137.75 million$138.10 millionViewN/AView Earnings Details
5/6/2015Q115$0.52$0.50$140.80 million$149.71 millionViewN/AView Earnings Details
2/23/2015Q414$0.57$0.32$158.15 million$117.10 millionViewListenView Earnings Details
11/10/2014Q314$0.56$0.61$165.10 million$164.60 millionViewN/AView Earnings Details
8/18/2014Q214$0.46$0.52$134.07 million$162.80 millionViewListenView Earnings Details
5/12/2014Q114$0.45$0.44$130.93 million$139.70 millionViewN/AView Earnings Details
3/3/2014Q413$0.43$0.39$115.22 million$110.10 millionViewN/AView Earnings Details
11/6/2013Q313$0.37$0.36$97.09 million$97.30 millionViewN/AView Earnings Details
8/8/2013Q2 2013$0.54$0.62$138.20 million$143.60 millionViewN/AView Earnings Details
5/9/2013Q1 2013$0.35$0.36$91.69 million$91.80 millionViewN/AView Earnings Details
3/1/2013Q4 2012$0.31$0.34$86.08 million$86.10 millionViewN/AView Earnings Details
11/5/2012Q312$0.33$0.32$85.03 million$85.20 millionViewN/AView Earnings Details
8/2/2012$0.44$0.52ViewN/AView Earnings Details
5/3/2012$0.27$0.29ViewN/AView Earnings Details
2/23/2012$0.28$0.24ViewN/AView Earnings Details
11/9/2011$0.27$0.28ViewN/AView Earnings Details
7/27/2011$0.39$0.39ViewN/AView Earnings Details
4/27/2011$0.24$0.25ViewN/AView Earnings Details
2/28/2011$0.21$0.20ViewN/AView Earnings Details
11/10/2010Q3 2010$0.25$0.25ViewN/AView Earnings Details
7/28/2010Q2 2010$0.38$0.38ViewN/AView Earnings Details
4/29/2010Q1 2010$0.23$0.15ViewN/AView Earnings Details
3/2/2010Q4 2009$0.19$0.17ViewN/AView Earnings Details
10/28/2009Q3 2009$0.26$0.28ViewN/AView Earnings Details
7/30/2009Q2 2009$0.42$0.45ViewN/AView Earnings Details
5/7/2009Q1 2009$0.24$0.23ViewN/AView Earnings Details
3/2/2009Q4 2008$0.06$0.34ViewN/AView Earnings Details
11/6/2008Q3 2008$0.24$0.08ViewN/AView Earnings Details
8/11/2008Q2 2008$0.21$0.36ViewN/AView Earnings Details
5/8/2008Q1 2008($0.01)($0.08)ViewN/AView Earnings Details
3/4/2008Q4 2007$0.15($0.01)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

PDL Biopharma (NASDAQ:PDLI) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/4/2016quarterly$0.056.25%6/2/20166/6/20166/13/2016
2/1/2016quarterly$0.057.27%3/2/20163/4/20163/11/2016
2/2/2015quarterly$0.158.22%6/1/20166/5/20166/12/2016
1/30/2015quarterly$0.158.23%6/3/20156/5/20156/12/2015
1/30/2015quarterly$0.158.23%3/3/20153/5/20153/12/2015
1/30/2015quarterly$0.158.23%12/2/201512/4/201512/11/2015
1/30/2015quarterly$0.158.23%9/2/20159/4/20159/11/2015
1/31/2014quarterly$0.156.59%9/3/20149/5/20149/12/2014
1/31/2014quarterly$0.156.59%3/3/20143/5/20143/12/2014
1/31/2014quarterly$0.156.59%12/3/201412/5/201412/12/2014
1/31/2014quarterly$0.156.59%6/3/20146/5/20146/12/2014
1/31/2013quarterly$0.158.72%12/3/201312/5/201312/12/2013
1/31/2013quarterly$0.158.72%6/3/20136/5/20136/12/2013
1/31/2013quarterly$0.158.72%9/3/20139/5/20139/12/2013
1/30/2013quarterly$0.158.72%3/1/20133/5/20133/12/2013
(Data available from 1/1/2013 forward)

Insider Trades

PDL Biopharma (NASDAQ PDLI) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 2.30%
Institutional Ownership Percentage: 90.57%
Insider Trading History for PDL Biopharma (NASDAQ:PDLI)
Institutional Ownership by Quarter for PDL Biopharma (NASDAQ:PDLI)

PDL Biopharma (NASDAQ PDLI) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/24/2017Peter S GarciaVPBuy25,000$1.98$49,500.00452,492View SEC Filing  
8/9/2016Peter S GarciaVPBuy10,000$3.00$30,000.00232,092View SEC Filing  
12/15/2015Peter S. GarciaCFOBuy5,000$3.64$18,200.00126,041View SEC Filing  
12/14/2015Peter S. GarciaCFOBuy10,000$3.42$34,200.00126,041View SEC Filing  
12/7/2015Steffen PietzkeCAOBuy20,590$3.64$74,947.60View SEC Filing  
8/14/2015Peter S GarciaCFOBuy20,000$5.83$116,600.00View SEC Filing  
11/26/2014Harold E SelickDirectorBuy6,000$8.08$48,480.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

PDL Biopharma (NASDAQ PDLI) News Headlines

Source:
DateHeadline
PDL BioPharma (PDLI) Presents At 2018 UBS Global Healthcare Conference - SlideshowPDL BioPharma (PDLI) Presents At 2018 UBS Global Healthcare Conference - Slideshow
seekingalpha.com - May 23 at 5:11 PM
PDL BioPharma Names Dr. Jill Jene Vice President, Business DevelopmentPDL BioPharma Names Dr. Jill Jene Vice President, Business Development
finance.yahoo.com - May 21 at 4:53 PM
PDL BioPharmas (PDLI) CEO John McLaughlin on Q1 2018 Results - Earnings Call TranscriptPDL BioPharma's (PDLI) CEO John McLaughlin on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 12 at 9:12 AM
Edited Transcript of PDLI earnings conference call or presentation 9-May-18 8:30pm GMTEdited Transcript of PDLI earnings conference call or presentation 9-May-18 8:30pm GMT
finance.yahoo.com - May 11 at 5:18 PM
PDL BioPharma Inc. Q1 adjusted earningsPDL BioPharma Inc. Q1 adjusted earnings
www.nasdaq.com - May 9 at 5:06 PM
PDL BioPharma EPS of $0.01PDL BioPharma EPS of $0.01
seekingalpha.com - May 9 at 5:06 PM
PDL BioPharma: 1Q Earnings SnapshotPDL BioPharma: 1Q Earnings Snapshot
finance.yahoo.com - May 9 at 5:06 PM
PDL BioPharma Announces First Quarter 2018 Financial ResultsPDL BioPharma Announces First Quarter 2018 Financial Results
finance.yahoo.com - May 9 at 5:06 PM
PDL Biopharma (PDLI) Receives Average Rating of "Hold" from AnalystsPDL Biopharma (PDLI) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - May 7 at 11:38 AM
Attention Deficit Hyperactivity Disorder (ADHD): Market Intelligence Review and Insights 2018 - ResearchAndMarkets ...Attention Deficit Hyperactivity Disorder (ADHD): Market Intelligence Review and Insights 2018 - ResearchAndMarkets ...
www.businesswire.com - May 3 at 4:59 PM
Checkpoint Inhibitors for Treating Cancer Market Report 2018-2028 - Visiongain ReportCheckpoint Inhibitors for Treating Cancer Market Report 2018-2028 - Visiongain Report
www.prnewswire.com - May 1 at 4:55 PM
PDL Biopharma: Activist Investor, Enter Stage RightPDL Biopharma: Activist Investor, Enter Stage Right
seekingalpha.com - April 27 at 4:56 PM
PDL Biopharma (PDLI) to Release Earnings on TuesdayPDL Biopharma (PDLI) to Release Earnings on Tuesday
www.americanbankingnews.com - April 24 at 8:24 AM
 Brokerages Anticipate PDL Biopharma (PDLI) to Announce $0.06 Earnings Per Share Brokerages Anticipate PDL Biopharma (PDLI) to Announce $0.06 Earnings Per Share
www.americanbankingnews.com - April 24 at 3:20 AM
PDL Biopharma (PDLI) Lowered to "Buy" at BidaskClubPDL Biopharma (PDLI) Lowered to "Buy" at BidaskClub
www.americanbankingnews.com - April 19 at 12:49 PM
Form 8-K PDL BIOPHARMA, INC. For: Apr 16Form 8-K PDL BIOPHARMA, INC. For: Apr 16
www.streetinsider.com - April 17 at 5:28 PM
Technical Perspectives on Biotech Stocks -- Pain Therapeutics, Paratek Pharma, PDL BioPharma, and Progenics PharmaTechnical Perspectives on Biotech Stocks -- Pain Therapeutics, Paratek Pharma, PDL BioPharma, and Progenics Pharma
www.bizjournals.com - April 16 at 8:44 AM
PDL BioPharma to Hold Annual Meeting of Stockholders on June 8, 2018PDL BioPharma to Hold Annual Meeting of Stockholders on June 8, 2018
finance.yahoo.com - April 16 at 8:44 AM
BidaskClub Downgrades PDL Biopharma (PDLI) to SellBidaskClub Downgrades PDL Biopharma (PDLI) to Sell
www.americanbankingnews.com - April 14 at 10:43 AM
Head-To-Head Survey: Curis (CRIS) versus PDL Biopharma (PDLI)Head-To-Head Survey: Curis (CRIS) versus PDL Biopharma (PDLI)
www.americanbankingnews.com - April 14 at 1:11 AM
PDL Biopharma (PDLI) Given Average Recommendation of "Buy" by AnalystsPDL Biopharma (PDLI) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - April 12 at 11:47 AM
PDL Biopharmas (PDLI) "Buy" Rating Reiterated at Piper JaffrayPDL Biopharma's (PDLI) "Buy" Rating Reiterated at Piper Jaffray
www.americanbankingnews.com - April 10 at 10:30 PM
PDL BioPharma (PDLI) Presents At H. C. Wainwright Global Life Sciences Conference - SlideshowPDL BioPharma (PDLI) Presents At H. C. Wainwright Global Life Sciences Conference - Slideshow
seekingalpha.com - April 10 at 5:05 PM
PDL BioPharma Shareholder, SevenSaoi Capital, Comments on the Nomination of Shlomo Yanai to the PDL Board of Directors and Delivers Letter to the Board Outlining Significant ConcernsPDL BioPharma Shareholder, SevenSaoi Capital, Comments on the Nomination of Shlomo Yanai to the PDL Board of Directors and Delivers Letter to the Board Outlining Significant Concerns
finance.yahoo.com - April 10 at 9:05 AM
PDL Biopharma (PDLI) Rating Lowered to Hold at ValuEnginePDL Biopharma (PDLI) Rating Lowered to Hold at ValuEngine
www.americanbankingnews.com - April 9 at 11:35 AM
ValuEngine Upgrades PDL Biopharma (PDLI) to BuyValuEngine Upgrades PDL Biopharma (PDLI) to Buy
www.americanbankingnews.com - April 8 at 11:17 AM
 Analysts Anticipate PDL Biopharma (PDLI) Will Announce Earnings of $0.06 Per Share Analysts Anticipate PDL Biopharma (PDLI) Will Announce Earnings of $0.06 Per Share
www.americanbankingnews.com - April 7 at 3:22 AM
PDL Biopharma (PDLI) Rating Increased to Hold at BidaskClubPDL Biopharma (PDLI) Rating Increased to Hold at BidaskClub
www.americanbankingnews.com - April 6 at 10:46 AM
PDL Biopharmas (PDLI) "Hold" Rating Reiterated at CowenPDL Biopharma's (PDLI) "Hold" Rating Reiterated at Cowen
www.americanbankingnews.com - April 4 at 5:52 PM
PDL BioPharma to Present at the H.C. Wainwright Global Life Sciences ConferencePDL BioPharma to Present at the H.C. Wainwright Global Life Sciences Conference
finance.yahoo.com - April 3 at 5:05 PM
Is PDL BioPharma, Inc. a Buy?Is PDL BioPharma, Inc. a Buy?
finance.yahoo.com - March 27 at 9:05 AM
Arena's (ARNA) Etrasimod Meets Phase II Colitis Study GoalArena's (ARNA) Etrasimod Meets Phase II Colitis Study Goal
finance.yahoo.com - March 20 at 4:52 PM
PDL Biopharma (PDLI) Given Consensus Rating of "Hold" by AnalystsPDL Biopharma (PDLI) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - March 18 at 11:40 AM
Is PDL BioPharma (PDLI) a Great Stock for Value Investors Right Now?Is PDL BioPharma (PDLI) a Great Stock for Value Investors Right Now?
finance.yahoo.com - March 16 at 6:02 PM
PDL BioPharma (PDLI) Presents At 38th Annual Cowen And Company Healthcare Conference - SlideshowPDL BioPharma (PDLI) Presents At 38th Annual Cowen And Company Healthcare Conference - Slideshow
seekingalpha.com - March 14 at 6:31 PM
PDL BioPharma (PDLI) Upgraded at Zacks Investment ResearchPDL BioPharma (PDLI) Upgraded at Zacks Investment Research
www.americanbankingnews.com - March 14 at 12:44 PM
PDL BioPharma (PDLI) Lifted to C- at TheStreetPDL BioPharma (PDLI) Lifted to C- at TheStreet
www.americanbankingnews.com - March 13 at 12:19 PM
PDL BioPharma (PDLI) Q4 Earnings Beat, Revenues Rise Y/Y - NasdaqPDL BioPharma (PDLI) Q4 Earnings Beat, Revenues Rise Y/Y - Nasdaq
www.nasdaq.com - March 11 at 8:47 AM
PDL BioPharma (PDLI) Upgraded at BidaskClubPDL BioPharma (PDLI) Upgraded at BidaskClub
www.americanbankingnews.com - March 10 at 5:31 PM
PDL BioPharma Vaults on Q4 FiguresPDL BioPharma Vaults on Q4 Figures
www.baystreet.ca - March 9 at 6:13 PM
PDL BioPharma posts 4Q profitPDL BioPharma posts 4Q profit
finance.yahoo.com - March 8 at 6:06 PM
PDL BioPharma Announces Fourth Quarter and Year End 2017 Financial ResultsPDL BioPharma Announces Fourth Quarter and Year End 2017 Financial Results
finance.yahoo.com - March 8 at 6:06 PM
Will PDL BioPharma Inc (NASDAQ:PDLI) Continue To Underperform Its Industry?Will PDL BioPharma Inc (NASDAQ:PDLI) Continue To Underperform Its Industry?
finance.yahoo.com - March 8 at 8:57 AM
Quotidian Technical Highlights on Selected Biotech Stocks -- Paratek Pharma, PDL BioPharma, Progenics Pharma, and ProthenaQuotidian Technical Highlights on Selected Biotech Stocks -- Paratek Pharma, PDL BioPharma, Progenics Pharma, and Prothena
www.prnewswire.com - March 7 at 8:53 AM
Mackenzie Financial Corp Reduces Stake in PDL BioPharma Inc (PDLI)Mackenzie Financial Corp Reduces Stake in PDL BioPharma Inc (PDLI)
www.americanbankingnews.com - March 6 at 12:08 PM
PDL BioPharma Inc (PDLI) Expected to Post Earnings of $0.03 Per SharePDL BioPharma Inc (PDLI) Expected to Post Earnings of $0.03 Per Share
www.americanbankingnews.com - March 4 at 1:08 AM
PDL BioPharma to Announce Fourth Quarter / Year-End 2017 Financial Results on March 8, 2018PDL BioPharma to Announce Fourth Quarter / Year-End 2017 Financial Results on March 8, 2018
finance.yahoo.com - March 1 at 8:39 AM
PDL BioPharma (PDLI) Set to Announce Quarterly Earnings on MondayPDL BioPharma (PDLI) Set to Announce Quarterly Earnings on Monday
www.americanbankingnews.com - February 28 at 8:20 PM
Kestrel Investment Management Corp Sells 45,700 Shares of PDL BioPharma Inc (PDLI)Kestrel Investment Management Corp Sells 45,700 Shares of PDL BioPharma Inc (PDLI)
www.americanbankingnews.com - February 28 at 4:14 PM
PDL BioPharma Inc (PDLI) Stake Lessened by Fuller & Thaler Asset Management Inc.PDL BioPharma Inc (PDLI) Stake Lessened by Fuller & Thaler Asset Management Inc.
www.americanbankingnews.com - February 28 at 12:10 PM

SEC Filings

PDL Biopharma (NASDAQ:PDLI) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

PDL Biopharma (NASDAQ:PDLI) Income Statement, Balance Sheet and Cash Flow Statement

Chart

PDL Biopharma (NASDAQ PDLI) Stock Chart for Saturday, May, 26, 2018

Loading chart…

This page was last updated on 5/26/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.